VIM and lung cancer: To clarify the role of the intermediate filament protein vimentin in the epithelial-to-mesenchymal transition (EMT), we induced EMT in lung cancer cells with TGF-β1, followed by treatment with the drug ALD-R491, which targets vimentin.